MedTrace Logo

Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm

NCT06281977 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2025-12-17

No results posted yet for this study

Summary

The objective of this study is to determine if there is a meaningful benefit to using the sedative medication dexmedetomidine in the acute treatment of patients with recurrent ventricular arrhythmias, known as electrical storm. This will be a multi-centre, double-blinded, placebo-controlled, randomized trial. Patients with electrical storm will be randomized to receive 48 to 72 hours of dexmedetomidine or placebo as part of their initial treatment in an intensive care unit.

Conditions

  • Ventricular Tachycardia
  • Ventricular Arrhythmias
  • Ventricular Fibrillation
  • Recurrent Ventricular Tachycardia

Interventions

DRUG

Dexmedetomidine

Dose range: 0.3 mcg/kg/hr to 1 mcg/kg/hr.

DRUG

Normal saline

Programed as dexmedetomidine on infusion pump.

Sponsors & Collaborators

  • Ottawa Heart Institute Research Corporation

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-08
Primary Completion
2027-05-08
Completion
2027-08-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06281977 on ClinicalTrials.gov